Karuna Therapeutics (NASDAQ:KRTX) reported quarterly losses of $(2.38) per share. This is a 38.37 percent decrease over losses of $(1.72) per share from the same period last year.
RBC Capital Maintains Outperform on TELUS, Raises Price Target to C$34
RBC Capital analyst Drew McReynolds maintains TELUS (TSX:T) with a Outperform and raises the price target from C$33 to C$34.
